DexTech Medical's application for myeloma study approved
The application for a phase1 study regarding OsteoDex's effect on patients with multiple myeloma that was submitted to the Medical Products Agency on 2022-06-23 has been approved and granted permission 2022-08-10. The study will include 20 patients and be conducted at 5 hospital centers in Sweden and Norway. The start of the study is expected to be Q3-2022 - Q1-2023 and is expected to be completed Q3-2024. For more information about DexTech, please contact: Gösta Lundgren – CFO DexTech Medical AB Phone: +46 (0) 707104788 E-post: gosta.lundgren@dextechmedical.com This